| 產(chǎn)品描述： | STAT5-IN-1 是一種有效的選擇性 STAT5 抑制劑，其對(duì)于STAT5β亞型的IC50值為47 μM |
| 靶點(diǎn)： |
STAT5β(Cell-free assay):47 μM;STAT |
| 體外研究： |
STAT5-IN-1, the STAT5 phosphorylation specific inhibitor, selectively blocks the STAT5 signaling and decreases the percentage of CD4+CD25+Foxp3+ Tregs after SEC2 stimulation on murine splenocytes |
| 體內(nèi)研究： |
STAT5-IN-1, a STAT5 inhibitor, significantly attenuates atherosclerosis in ApoE-/- mice induced by HFD via decreasing inflammation. |
| 細(xì)胞實(shí)驗(yàn)： |
Cell lines: murine splenocytes Concentrations: 0.47 mM Incubation Time: 3 days Method: Fresh murine splenocytes seeded in 24-well flat-bottom plates are treated with each inhibitor at final concentrations of 10 μM LY294002, 10 mM Trigonelline, 0.47 mM STAT5-IN-1, 50 μM SB431542, and 1 μM SIS3, or treated with 10 μg/mL anti-IL-2 neutralizing antibody, respectively, then cells are stimulated with 104 ng/mL SEC2 for 3 days in a humidified incubator at 37 ℃ with 5% CO2. |
| 動(dòng)物實(shí)驗(yàn)： |
Animal Models: ApoE-/- mice Dosages: 10 mg/kg Administration: p.o. |
| 參考文獻(xiàn)： |
1. Müller J, et al. Discovery of chromone-based inhibitors of the transcription factor STAT5. Chembiochem. 2008 Mar 25;9(5):723-7. 2. Li Y, et al. Induction of CD4+ regulatory T cells by stimulation with Staphylococcal Enterotoxin C2 through different signaling pathways. Biomed Pharmacother. 2021 Nov;143:112204. 3. Wang X, et al. STAT5 inhibitor attenuates atherosclerosis via inhibition of inflammation: the role of STAT5 in atherosclerosis. Am J Transl Res. 2021;13(3):1422-1431. |
| 溶解性： |
Soluble in DMSO |
| 保存條件： |
-20℃ |
| 配置溶液濃度參考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.41 ml |
17.049 ml |
34.097 ml |
| 5 mM |
0.682 ml |
3.41 ml |
6.819 ml |
| 10 mM |
0.341 ml |
1.705 ml |
3.41 ml |
| 50 mM |
0.068 ml |
0.341 ml |
0.682 ml |
|
| 注意： |
部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶(hù)參考交流研究之用。 |
上海工商
危險(xiǎn)品化學(xué)品經(jīng)營(yíng)許可證（不帶存儲(chǔ)）
營(yíng)業(yè)執(zhí)照(三證合一)
北京